SCHEMBL6804167

SCHEMBL6804167

COC(=O)c1cccc(-c2cc(F)ccc2NC(=O)C(C)(C)C)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
PDK2 Q15119 4/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
PDK1 Q15118 2/20 0.44
PDK3 Q15120 2/20 0.44
PDK4 Q16654 2/20 0.44
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ABL1 P00519 1/20 0.39
SLC6A2 P23975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13824011 0.80 SLC6A3 (0.54) KDM4EPDK2SLC6A4SLC6A3CYP1A2
SCHEMBL19923176 0.78 SLC6A3 (0.59) KDM4EPDK2SLC6A4SLC6A3CYP1A2
SCHEMBL13824199 0.73 SLC6A3 (0.77) KDM4EPDK2SLC6A4SLC6A3CYP1A2
SCHEMBL13824070 0.72 SLC6A3 (0.53) KDM4EPDK2SLC6A4SLC6A3TSHR
SCHEMBL24506561 0.72 KDM4E (0.65) KDM4ECYP1A2CYP2D6TSHRCYP2C19
SCHEMBL13824067 0.72 SLC6A3 (0.56) KDM4EPDK2SLC6A4SLC6A3CYP1A2
SCHEMBL9987583 0.71 KDM4E (0.52) KDM4EPDK2SLC6A4SLC6A3PDK1
SCHEMBL14254877 0.71 HTT (0.60) CYP1A2CYP2C19ALDH1A1NPC1RAB9A
SCHEMBL825285 0.71 KDM4E (0.55) KDM4EPDK2PDK1PDK3PDK4
SCHEMBL9987490 0.71 PDK1 (0.73) KDM4EPDK2PDK1PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266774-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed
US-6770667-B1 N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-03 US disclosed
EP-1216240-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-06-26 EP disclosed
WO-2001025229-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266774-A1 Amide compounds TPH1, HTR1A, HTR5A KDM4E 2363/4885PDK2 2998/4885SLC6A4 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.